ClinicalTrials.gg
CompletedNCT02406989Updated Mar 16, 2016

A Multiple-Ascending Dose Study of MS-553 in Healthy Volunteers

A Phase 1 interventional study of MS-553 and Placebo in Safety and PK in Healthy Volunteers, sponsored by MingSight Pharmaceuticals Pty Limited. Completed at 1 site in Australia. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-03-16.

Sponsored by MingSight Pharmaceuticals Pty Limited · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Study summary

This is a randomized, double-blind, placebo-controlled, multiple-ascending dose study of MS-553 in healthy volunteers. Endpoints are safety, tolerability, and pharmacokinetics. Subjects are dosed for 14 days.

02

Conditions studied

  • Safety and PK in Healthy Volunteers
03

In context

Lead sponsor

This is the only study on the registry with MingSight Pharmaceuticals Pty Limited as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • In good general health with 18 to 32 kg/m2. Females must be nonpregnant, nonlactating, at least 2 years or surgically sterilized at least 6 months prior

Exclusion criteria

Exclusion Criteria:

  • History of skin rash, migraine, or ocular diseases, conditions predisposing to
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    MS-553

    MS-553 oral tablet BID x 14 days

    Drug: MS-553

  • Placebo comparator
    Placebo

    Placebo oral tablet BID x 14 days

    Drug: Placebo

Interventions

  • DrugMS-553

    Study Drug

  • DrugPlacebo

    Matching placebo to MS-553

06

What researchers measure

Primary outcomes

  1. Number of Subjects with Adverse Events as a Measure of Safety and Tolerability

    Time frame: 14 days

Secondary outcomes

  1. Peak Plasma Concentration (Cmax)

    Time frame: 14 days

  2. Area under the Plasma Concentration versus Time Area under the Plasma Concentration versus Time Curve

    Time frame: 14 days

07

Study locations

1 site
  • Nucleus Network
    Melbourne, Victoria 3122, Australia
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2015, a primary completion of Aug 2015 and a completion of Sep 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 25, 2015
First posted
Apr 2, 2015
Start
Apr 2015
Primary completionActual
Aug 2015
CompletionActual
Sep 2015
Last update
Mar 16, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 16, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02406989
Lead sponsor
MingSight Pharmaceuticals Pty Limited
Responsible party
Sponsor
First posted
Apr 2, 2015
Start date
Apr 2015
Primary completion
Aug 2015
Completion
Sep 2015
Last update
Mar 16, 2016

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: PKC-beta Inhibitor MS-553

Start the discussion